Tarsus Pharmaceuticals/$TARS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Ticker

$TARS
Primary listing

Industry

Pharmaceuticals

Employees

323

ISIN

US87650L1035

TARS Metrics

BasicAdvanced
$1.7B
-
-$2.72
0.94
-

What the Analysts think about TARS

Analyst ratings (Buy, Hold, Sell) for Tarsus Pharmaceuticals stock.

Bulls say / Bears say

Tarsus Pharmaceuticals secured a $200 million non-dilutive financing commitment from Pharmakon Advisors, enhancing its financial flexibility and supporting future growth initiatives. (globenewswire.com)
The company reported a 407.9% increase in revenue to $66.41 million for the quarter ended December 31, 2024, surpassing analyst expectations and indicating strong market demand for its products. (tradingview.com)
Analysts have raised their price targets for Tarsus Pharmaceuticals, with Oppenheimer increasing its target to $65.00 and maintaining an 'outperform' rating, reflecting confidence in the company's growth prospects. (mayfieldrecorder.com)
Insider selling activity, including the sale of 8,355 shares by Dianne Whitfield, may raise concerns about internal confidence in the company's future performance. (stocknews.com)
The company's stock experienced a 17.8% decline in the quarter ending December 31, 2024, which could indicate investor apprehension despite strong financial results. (tradingview.com)
While Tarsus Pharmaceuticals has received positive analyst ratings, the consensus target price of $54.20 suggests limited upside potential from current levels, which may temper investor enthusiasm. (techdows.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.

TARS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TARS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TARS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs